Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

Rhea-AI Summary

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has appointed Prathyusha Duraibabu as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Duraibabu, who previously served as Principal Accounting Officer, brings over 20 years of experience in financial strategy and operations. Her notable contributions include orchestrating a $140 million follow-on offering and aiding collaborations with Biogen and Novartis, raising an additional $425 million. CEO Sandy Macrae highlighted her leadership and experience in enhancing organizational efficiency.

Positive

• Appointment of Prathyusha Duraibabu is expected to strengthen financial leadership.
• Duraibabu's past initiatives have raised $565 million through offerings and collaborations.
• Duraibabu has a proven track record in optimizing financial strategies.

Negative

• Transitioning to a new CFO may present short-term continuity challenges.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer.

“Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams,” said Sandy Macrae, Chief Executive Officer of Sangamo. “I look forward to Prathyusha’s leadership and savvy which will bolster our growing genomic medicine company.”

Ms. Duraibabu joined Sangamo in March 2019 with over 20 years of experience and has built out the financial planning and analysis, controllership, audit, procurement, and compliance teams and functions. She orchestrated a $140 million follow on offering and contributed to successful collaboration agreements with Biogen and Novartis, raising an additional $425 million. She has also spearheaded several successful business process initiatives and system implementations to drive operational efficiencies. Prior to joining Sangamo, Ms. Duraibabu served as the Corporate Controller at Pacific Biosciences. She received her Master of Business Administration from San Jose State University, her Bachelors of Accounting from Oxford Brookes University and is a Certified Public Accountant.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005151/en/

FAQ

Who has been appointed as the new CFO of Sangamo Therapeutics?

Prathyusha Duraibabu has been appointed as the new CFO of Sangamo Therapeutics.

What experience does Prathyusha Duraibabu bring to her role as CFO?

Prathyusha Duraibabu brings over 20 years of financial experience, including roles in optimizing financial strategy and operations.

What significant financial achievements has Prathyusha Duraibabu accomplished at Sangamo?

She orchestrated a $140 million follow-on offering and secured collaborations with Biogen and Novartis, raising an additional $425 million.

When did Prathyusha Duraibabu assume her role as CFO at Sangamo?

Prathyusha Duraibabu assumed her role as CFO on June 1, 2021.

What is Sangamo Therapeutics' focus in the biotech field?

Sangamo Therapeutics focuses on genomic medicines, including gene therapy, cell therapy, and genome engineering.